PEDIATRIC CANCER
SURVIVAL RATES
The 83-85% overall five-year survival conceals enormous variation. Standard-risk ALL approaches 95%+. DIPG median OS is 9-11 months. The average is almost useless for any specific family.
What This Means for Patients
Survival by type: ALL ~90% (standard-risk B-ALL 95%+); brain tumours vary enormously (low-grade glioma 80-90%+, DIPG <10% at 2 years); Hodgkin lymphoma 95-97%; neuroblastoma low-risk >90%, high-risk ~40-50%; Wilms tumour ~90%; osteosarcoma localised 65-75%, metastatic 20-30%; AML 60-70%. Population
Key Insights
Understanding this area is essential for informed decisions in pediatric oncology.
Clinical Relevance
Directly impacts treatment planning, eligibility, and outcomes for children with cancer. Discuss with your pediatric oncology team how this applies to your child's specific situation.
For Families
Knowledge in this area enables better-informed questions, more productive consultations, and active participation in treatment decisions alongside the clinical team.
Benefits and Limitations
Benefits
- Pediatric oncology has invested heavily in systematic evidence-based improvement
- Cooperative group infrastructure provides the strongest trial framework in medicine
- Advanced therapies extending options for relapsed and high-risk disease
Limitations
- Not all pediatric cancers have benefited equally from advances
- Geographic access to specialist centres and programmes remains a barrier
- Some toxicities and challenges remain without full preventive solutions
Frequently Asked Questions
About This Topic
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Navigating Pediatric Cancer Treatment?
CancerFax connects families with specialist pediatric oncology centres, advanced therapy access, and clinical trial opportunities for childhood cancers.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.